Result of AGM
04 5월 2010 - 10:17PM
UK Regulatory
TIDMCMSH
RNS Number : 2826L
China Medical Systems Holdings Ltd
04 May 2010
+------------------------------+------------------------------+
| For immediate release | 4 May 2010 |
+------------------------------+------------------------------+
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR
JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF
THE RELEVANT LAWS OR REGULATION.
China Medical System Holdings Ltd.
("CMS" or "the Company")
Change in Directorate and Results of Annual General Meeting
China Medical System Holdings Ltd. (AIM: CMSH), a provider of sales, marketing
and promotion services for prescription pharmaceutical products in China,
announces that Dr. Paul Harper ("Dr. Harper"), an Independent Non-executive
Director ("INED") of the Company, ceased to be a Director of the Company upon
his resignation from the board of Directors of the Company (the "Board") at the
conclusion of the Company's Annual General Meeting held on 4 May 2010 ("AGM").
At the AGM, an ordinary resolution was passed to appoint Dr. Huaizheng Peng
("Dr. Peng") as an INED of the Company, such appointment became effective at the
conclusion of the AGM. Upon his appointment as an INED of the Company, Dr. Peng
was also appointed as the Chairman of the Remuneration Committee of the Company,
and a committee member of each of the Audit Committee and the Nomination
Committee of the Company.
Dr. Huaizheng Peng is a partner of Northland Bancorp, a private equity firm with
its current primary goal to invest in financial services globally. Before he
joined Northland Bancorp, he was the head of life sciences and a director of
corporate finance in Seymour Pierce, a London-based investment bank and
stockbroker. From 1999 to 2006, Dr. Peng was a senior portfolio manager,
specialising in global life science and Asian technology investment at Reabourne
Technology Investment Management Limited. Dr. Peng received his bachelor's
degree in medicine from Hunan Medical College (now Central South University
Siangya School of Medicine) in Changsha, Hunan Province, China in 1984, and
subsequently, a master's degree in medicine from Hunan Medical College in 1989.
He was awarded his PhD in molecular pathology from University College London
(UCL) Medical School, London, UK, in 1998 and practiced as a clinical lecturer
at the UCL Medical School, London, UK. In addition, from 2006 to 2008, he was a
non-executive director of China Medstar, an AIM listed medical device company.
Commenting on the change of Directors, Mr. Lam Kong, CEO of CMS, said: "The
Board would like to take this opportunity to express its gratitude to Dr. Harper
for his services and contributions to the Company during his tenure of office as
a director of the Company. We wish all the best for his future. I welcome Dr.
Peng on board. His unique wide spectrum of experience in global life sciences
industry and financial services industry will add more value to our business".
In addition, The Company is pleased to announce that all the resolutions set out
in the Notice of the meeting for the AGM held on 4 May 2010 were duly passed by
shareholders.
Save as disclosed below, there is no further information in respect of Dr.
Peng's appointment required to be disclosed pursuant to paragraph (g) of
Schedule 2 to the AIM Rules for Companies.
Dr. Peng currently holds the following directorships:
Galileo Global Equity Advisors Inc.
Dr. Peng has held the following directorships in the last five years:
China Medstar Limited
Dr. Peng does not currently hold any shares in, or options over shares in, the
capital of the Company.
For further information, please contact:
+-------------------------------+-------------------+
| China Medical System Holdings | + (852) 2369 3889 |
| Ltd | |
+-------------------------------+-------------------+
| Vincent Hui | |
| | |
+-------------------------------+-------------------+
| Seymour Pierce Limited | + 44 (0)20 7107 |
| | 8344 |
+-------------------------------+-------------------+
| Chris Howard | |
+-------------------------------+-------------------+
The information contained in this document is not for release, publication or
distribution, directly or indirectly, in whole or in part, in, into or from in
the United States of America (including its territories and possessions, any
state of the United States and the District of Columbia). These materials do not
contain, constitute or form part of an offer to sell or the solicitation of an
offer to purchase securities in the United States. The securities referred to
herein (the "Securities") have not been and will not be registered under the US
Securities Act of 1933, as amended (the "Securities Act"), and may not be
offered or sold in the United States absent registration under the Securities
Act except pursuant to an available exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act. There will be
no public offer of the Securities in the United States.
China Medical System Holdings Limited
China Medical System Holdings Ltd., (CMS) is listed on the Alternative
Investment Market (AIM) of the London Stock Exchange with the ticker symbol
"CMSH". It is a provider of sales, marketing and promotion services for
prescription pharmaceutical products in China. For further information, please
visit www.chinamedicalsystem.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUSAORRVAVRAR
China Medical (LSE:CMSH)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
China Medical (LSE:CMSH)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
